• Daniele Scartoni, Isacco Desideri, Irene Giacomelli, Vanessa Di Cataldo, Lucia Di Brina, Anna Mancuso, Ilaria Furfaro, Pierluigi Bonomo, Gabriele Simontacchi, and Lorenzo Livi.
• Department of Radiation Oncology, University of Florence, Florence, Italy scartoni_daniele@libero.it.
• Anticancer Res. 2015 Oct 1; 35 (10): 5687-92.

AimThe present phase II study aimed to evaluate the tolerance and safety of Dixentil, a nutritional supplement based on zinc with the addition of prebiotics (galacto-oligosaccharides), tyndalized probiotics (Lactobacillus acidophilus and L. casei) and vitamins B1, B2 and B6, and nicotinamide), given as prophylaxis to patients undergoing pelvic radiotherapy and its efficacy in the prevention and reduction of radiation-related gastrointestinal disorders.Patients And MethodsForty consecutive patients who were candidates for pelvic radiotherapy received Dixentil before starting and during radiotherapy. The primary end-point was to evaluate the safety and tolerance of Dixentil. Secondary end-points were incidence and severity of radiation-induced diarrhea and number of patients who discontinued radiotherapy because of diarrhea.ResultsRadiation-induced enteritis occurred in 17 patients, grade I and grade II diarrhea was documented in 14 and 3 patients respectively; no grade III or IV diarrhea was observed. Radiotherapy was discontinued due to treatment-induced enteritis only in two patients for 6 days.ConclusionUse of Dixentil is an easy, safe, and feasible approach to protect patients against the risk of radiation-induced diarrhea.Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

34 keywords...

hide…